{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T09:27:20Z","timestamp":1777368440035,"version":"3.51.4"},"reference-count":36,"publisher":"Cambridge University Press (CUP)","license":[{"start":{"date-parts":[[2018,12,3]],"date-time":"2018-12-03T00:00:00Z","timestamp":1543795200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2018,12,3]],"date-time":"2018-12-03T00:00:00Z","timestamp":1543795200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.cambridge.org"],"crossmark-restriction":true},"short-container-title":["Epidemiol. Infect."],"published-print":{"date-parts":[[2019]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The mumps vaccine is not included in the national immunisation programme (NIP) of approximately 80 countries including Japan. To investigate the vaccine's cost-effectiveness, we developed a dynamic transmission model for routine one- and two-dose mumps vaccination programs in Japan. We calculated the incremental cost-effectiveness ratio compared with a current programme over a projected 50-year period. We created a Japanese population model and performed dynamic simulation to estimate the number of patients enrolled in the current programme, the routine one-dose programme, and the routine two-dose programme over the next 50 years using the Berkeley Madonna program. We estimated the medical and social costs of natural mumps infections and vaccinations to analyse cost-effectiveness. Finally, we performed a sensitivity analysis with parameters including vaccine cost, vaccine efficacy, medical costs per case, social costs per case, incidence of adverse events and discount rate. Base case analysis showed that both the one-dose and two-dose programmes predominated and that quality-adjusted life years (QALYs) were saved, compared with the current programme. The medical costs, total cost and QALYs saved during the study period in the two-dose programme compared with the current programme were 217 billion JPY, 860 billion JPY and 184 779, respectively. The two-dose programme surpassed the one-dose programme throughout the study period. In all the scenarios of the sensitivity analysis, two-dose vaccination was better than the one-dose programme. This simulation confirmed that the routine two-dose vaccination programme was more cost-effective and QALY-saving than either the one-dose programme or the current programme. Because of the variability of the results between the various models, further simulations with different models should be conducted.<\/jats:p>","DOI":"10.1017\/s0950268818003230","type":"journal-article","created":{"date-parts":[[2018,12,3]],"date-time":"2018-12-03T06:07:50Z","timestamp":1543817270000},"update-policy":"https:\/\/doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":4,"title":["Dynamic transmission model of routine mumps vaccination in Japan"],"prefix":"10.1017","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0623-066X","authenticated-orcid":false,"given":"Taito","family":"Kitano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2018,12,3]]},"reference":[{"key":"S0950268818003230_ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.09.068"},{"key":"S0950268818003230_ref23","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-13-175"},{"key":"S0950268818003230_ref5","doi-asserted-by":"publisher","DOI":"10.7774\/cevr.2017.6.2.120"},{"key":"S0950268818003230_ref7","volume-title":"Infectious Disease Surveillance Annual Report","year":"2017"},{"key":"S0950268818003230_ref21","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X12454578"},{"key":"S0950268818003230_ref25","doi-asserted-by":"publisher","DOI":"10.3201\/eid2001.130019"},{"key":"S0950268818003230_ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.06.084"},{"key":"S0950268818003230_ref10","first-page":"386","article-title":"Mumps vaccine: present and future situation","volume":"38","author":"Ihara","year":"2010","journal-title":"Rinsyou Uirusu"},{"key":"S0950268818003230_ref19","doi-asserted-by":"publisher","DOI":"10.1016\/0047-2727(94)90012-4"},{"key":"S0950268818003230_ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)92311-X"},{"key":"S0950268818003230_ref16","volume-title":"Making Choices in Health: WHO Guide to Cost-Effectiveness Analysis","author":"Tan-Torres","year":"2003"},{"key":"S0950268818003230_ref9","volume-title":"The State of Population Aging","year":"2017"},{"key":"S0950268818003230_ref1","volume-title":"Media Center: Immunization Coverage","year":"2017"},{"key":"S0950268818003230_ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.05.020"},{"key":"S0950268818003230_ref8","volume-title":"Japan Statistical Yearbook","year":"2017"},{"key":"S0950268818003230_ref11","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1503\/cmaj.101371","article-title":"An assessment of mumps vaccine effectiveness by dose during an outbreak in Canada","volume":"183","author":"Shelley","year":"2011","journal-title":"Canadian Medical Association Journal"},{"key":"S0950268818003230_ref12","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1086\/588197","article-title":"Long-Term persistence of mumps antibody after receipt of 2 Measles-Mumps-Rubella (MMR) vaccinations and antibody response after a third MMR vaccination among a university population","volume":"197","author":"Anand","year":"2008","journal-title":"The Journal of Infectious Diseases"},{"key":"S0950268818003230_ref13","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00122-08"},{"key":"S0950268818003230_ref14","doi-asserted-by":"crossref","first-page":"140","DOI":"10.4161\/hv.26642","article-title":"Outbreak-related mumps vaccine effectiveness among a cohort of children and of young adults in Germany 2011","volume":"10","author":"Anja","year":"2014","journal-title":"Human Vaccines and Immunotherapeutics"},{"key":"S0950268818003230_ref15","volume-title":"Measles and Rubella Immunization Situation From 01\/04\/2015 to 31\/03\/2016","year":"2016"},{"key":"S0950268818003230_ref17","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-13-371"},{"key":"S0950268818003230_ref18","volume-title":"The Green Book: Appraisal and Evaluation in Central Government","author":"Treasury","year":"2011"},{"key":"S0950268818003230_ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2015.01.006"},{"key":"S0950268818003230_ref24","doi-asserted-by":"publisher","DOI":"10.1186\/2191-1991-2-19"},{"key":"S0950268818003230_ref26","first-page":"625","article-title":"Costs and benefits of measles and mumps immunization in Austria","volume":"57","author":"Wiedermann","year":"1979","journal-title":"Bulletin of the World Health Organization"},{"key":"S0950268818003230_ref27","doi-asserted-by":"publisher","DOI":"10.1155\/1997\/215175"},{"key":"S0950268818003230_ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2004.10.020"},{"key":"S0950268818003230_ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.02.070"},{"key":"S0950268818003230_ref30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0013392"},{"key":"S0950268818003230_ref31","volume-title":"WHO guide for Standardization of Economic Evaluations of Immunization Programmes","year":"2008"},{"key":"S0950268818003230_ref32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1703309"},{"key":"S0950268818003230_ref33","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1093\/aje\/kwu014","article-title":"Assessing mumps outbreak risk in highly vaccinated populations using spatial seroprevalence data","volume":"179","author":"Steven","year":"2014","journal-title":"American Journal of Epidemiology"},{"key":"S0950268818003230_ref34","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.vaccine.2013.11.021","article-title":"Mumps vaccine effectiveness and risk factors for disease in households during an outbreak in New York City","volume":"32","author":"Kara","year":"2014","journal-title":"Vaccine"},{"key":"S0950268818003230_ref35","first-page":"18914","article-title":"Increased mumps incidence in the Netherlands: review on the possible role of vaccine strain and genotype","volume":"13","author":"Kaaijk","year":"2008","journal-title":"Euro Surveillance"},{"key":"S0950268818003230_ref36","first-page":"174","article-title":"Mumps vaccine: progress toward the routine vaccination","volume":"42","author":"Toshiaki","year":"2014","journal-title":"Rinsyou Uirusu"},{"key":"S0950268818003230_ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.09.022"}],"container-title":["Epidemiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0950268818003230","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T17:44:45Z","timestamp":1559929485000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0950268818003230\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,3]]},"references-count":36,"alternative-id":["S0950268818003230"],"URL":"https:\/\/doi.org\/10.1017\/s0950268818003230","relation":{},"ISSN":["0950-2688","1469-4409"],"issn-type":[{"value":"0950-2688","type":"print"},{"value":"1469-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,3]]},"assertion":[{"value":"Copyright \u00a9 Cambridge University Press 2018\u00a0This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http:\/\/creativecommons.org\/licenses\/by\/4.0\/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.","name":"license","label":"License","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}}],"article-number":"e60"}}